DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Conivaptan
Conivaptan
The Science of Medicine. the Art of Healing. Going Lecture Free for Genz
AHFS Pharmacologic-Therapeutic Classification System
Conivaptan (Vaprisol )
Subject: Samsca (Tolvaptan) Original Effective Date: 07/27/15
Diuretics in Clinical Practice. Part I: Mechanisms of Action, Pharmacological Effects and 1
Mineralocorticoid Receptor Antagonists for Heart Failure with Reduced Ejection Fraction: Integrating Evidence Into Clinical Practice
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Hypernatremia: 2 Months Back When He Had Progressive Decrease in Vision (Right > Left)
The Syndrome of Inappropriate Antidiuretic Hormone: Current and Future Management Options
The V2 Receptor Antagonists
1 VAPRISOL (Conivaptan Hydrochloride Injection)
I in Un Torn Untuk Ta in an Atau Mana Na Anth
The Current Art of Diuretic Therapy for Heart Failure: a Personal Viewpoint
Hyponatremia
Drug Interaction Guideline for Drug Development and Labeling Recommendations (Draft for Public Comment)
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Stardrop Refernce Guide
University of Groningen Paving Ways for Personalizing Drug Therapy During Pregnancy Daud
Top View
Pharmacokinetics of Conivaptan Use in Patients with Severe Hepatic Impairment
Fluids and Diuretics
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
Download Download
Drugs Involved in Significant Pharmacokinetic Drug-Drug Interactions in 2015
Vaptans and Hyponatremia in Critical Patients
Examples of Prohibited and Permitted Substances And
Samsca, INN-Tolvaptan
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-Cov-2
Rational Management of Hospitalized Patients with Hyponatremia: Application to Patient Cases
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
The Treatment of Vasopressin V2-Receptor Antagonists in Cirrhosis Patients with Ascites
VAPRISOL® (Conivaptan Hydrochloride Injection)
Emerging Drug Therapies for Heart Failure
The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia
7-Renal Drugs FINAL
Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome
Changes Highlighted Final Version Date of Issue
Vasopressin Antagonists in the Treatment of Water-Retaining Disorders
VAPRISOL (Conivaptan Hydrochloride)
Conivaptan: a Step Forward in the Treatment of Hyponatremia?
Role of Diuretics and Ultrafiltration in Congestive Heart Failure
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Pharmacology/Therapeutics I Block Iv Handouts – 2017-18
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
DESCRIPTION VAPRISOL® (Conivaptan Hydrochloride Injection)
AHFS Pharmacologic-Therapeutic Classification System
Vaprisol (Conivaptan) Policy Number: C15199A
Official Protocol Title: NCT Number: NCT03055338 Document Date: 29-Mar-2017 a Phase Iia, Randomized, Double-Blind, Placebo- Cont
Conivaptan Monograph
Australian Public Assessment Report for Tolvaptan
Appendix C - Guidelines for IV Medication Administration
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
Hyponatremia Management
Learningpharmacology 2018.Pdf
ATC Code Title
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances